Hubbry Logo
search button
Sign in
Renovo plc
Renovo plc
Comunity Hub
MainMain
History
arrow-down
starMore
arrow-down
Sign in
Sign in
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Renovo plc
Renovo plc
Community hub for the Wikipedia article
logoWikipedian hub
Renovo plc
Renovo plc
Main
Welcome to the community hub built on top of the Renovo plc Wikipedia article. Here, you can discuss, collect, and organize anything related to Renovo plc. The purpose of the hub is to connect people, fos...
Add your contribution
Media Collections
0
Timelines
0
Articles
0
Notes collections
0
Days in Chronicle
0
Renovo plc

Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011.[2][3][4]

Key Information

Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5][6]

Products

[edit]

Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two in phase II clinical development, and numerous pre-clinical candidates.[7]

Drug Phase Action
Juvista Failed[8] Injecting into the wound margins around the time of surgery causes a prevention or reduction of scarring through the introduction of recombinant TGFβ3.
Adaprev Halted[9] Injected at the time of surgery to prevent and reduce scarring and adhesions between the tendon and surrounding tissues following tendon repair.
Prevascar Halted[10] Injection into the wound margins around the time of surgery reduces scarring by suppressing of TGFβ1 and TGFβ2.
Juvidex Renovo planned to partner with Juvidex as a cosmetic ingredient to improve skin appearance and to promote the healing of damaged skin.
RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.

References

[edit]
  1. ^ London Regenerative Medicine Network – January 2007 Meeting Archived 28 September 2007 at the Wayback Machine
  2. ^ Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.
  3. ^ Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  4. ^ Grogan, Kevin (31 May 2001). "Future bleak for Renovo with no workers or products". PharmaTimes. Retrieved 14 December 2016.
  5. ^ Rename Plan for Renovo (16 July 2014). InsiderMedia.com
  6. ^ "Company Overview of Inspired Capital plc". Bloomberg. Retrieved 14 December 2016.
  7. ^ Renovo – Products Archived 25 January 2010 at the Wayback Machine
  8. ^ "Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  9. ^ Ashcroft, Jamie. (18 November 2011) "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk.
  10. ^ Ashcroft, Jamie. (16 April 2012) "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk.
[edit]


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Hub tags